Loading...
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
BACKGROUND/AIM: We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. MATERIALS/METHODS: One hundred fifty two u‐HCC patients, who receive LEN treatment from Marc...
Na minha lista:
| Udgivet i: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6639201/ https://ncbi.nlm.nih.gov/pubmed/31127698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2241 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|